SMI of Bcl-2 TW-37 is active across a spectrum of B-cell tumors irrespective of their proliferative and differentiation status

The Bcl-2 family of proteins is critical to the life and death of malignant B-lymphocytes. Interfering with their activity using small-molecule inhibitors (SMI) is being explored as a new therapeutic strategy for treating B-cell tumors. We evaluated the efficacy of TW-37, a non-peptidic SMI of Bcl-2...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Al-Katib, Ayad M, Sun, Yuan, Goustin, Anton Scott, Azmi, Asfar Sohail, Chen, Ben, Aboukameel, Amro, Mohammad, Ramzi M
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2009
Sujets:
Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC2651908/
https://ncbi.nlm.nih.gov/pubmed/19220884
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-8722-2-8
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires